Internally administered targeted radionuclide therapy (TRT) with radio-labelled targeting molecules that deliver cytotoxic radiation to tumor has been used successfully to treat multiple cancers. Lu-177, used increasingly in TRT, emits both beta particles that deliver the therapeutic effect. FDA recently approved a fixed activity (4 cycles of 7.4 GBq/cycle as in NETTER -1) administered every 8 weeks. With the patient studies under this treatment, we collected CT images and corresponding volume of interest (organs, lesions) contours.
